PUBLIC COMPANY
saveAMGEN
USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
- phase1Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- phase3OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- phase1Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- phase3Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- phase3Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
- phase2A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- phase3A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
🐶 Hiring Signal
News
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 12h ago
- Amgen lays groundwork for new R&D center in HyderabadAmgen is expanding its footprint in India with an R&D center in Hyderabad, the latest by from the California company to boost its research facilities.fiercebiotech · 13h ago
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 1d ago
- Latigo IPO raises nearly $350M for pain drug developmentThe company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.biopharma_dive · 4d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 5d ago
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.fiercebiotech · 5d ago
- STAT+: Moderna launches early trial of Ebola mRNA vaccineNovo and Lilly earnings are out, Aurora Therapeutics slashing staff, and more biotech news from The Readoutstat · 6d ago
- Amgen’s MariTide stands alone after obesity cull while analysts seek more M&AAmgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…biospace · 6d ago
- Amgen culls early-stage obesity candidate, makes pipeline updatesAmgen is cutting its secretive early-stage obesity candidate, AMG 513. The company hasn’t revealed much about the Phase 1 program or why it’s being discontinued. When asked for more detail, a spoke…endpoints · 7d ago
- Amgen drops early-stage obesity drug, upping pressure on MariTideAmgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTide.fiercebiotech · 7d ago
comments(0)
5-min edit window · permanent after that